Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial

Summit Therapeutics (SMMT) on Sunday said ivonescimab significantly extended survival compared with Merck’s (MRK) Keytruda in ...
Fierce Pharma

Akeso, Summit’s ivonescimab tops Keytruda in lung cancer survival, with strong data in PD-L1-high patients

Akeso and Summit Therapeutics’ ivonescimab reduced the risk of death by 27% compared with Keytruda in patients with treatment ...
The Pharma Letter

Akeso jumps on ivonescimab's Keytruda beat

Chinese biopharma Akeso has reported positive overall survival (OS) data for ivonescimab against Merck & Co's Keytruda ...
Yahoo Finance

Keytruda fails lung and skin cancer trials, limiting further expansion

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Fierce Pharma

Increased deaths shadow AstraZeneca, Daiichi’s Enhertu first-line lung cancer data

A higher death risk in a phase 3 trial threatens to thwart AstraZeneca and Daiichi Sankyo’s bid to establish their star ...
Yahoo Finance

Summit’s checkpoint inhibitor trumps Keytruda in lung cancer trial

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The Pharma Letter

Ivonescimab beats Keytruda on survival in Akeso's first-line lung cancer trial

Chinese biopharmaceutical firm Akeso (HKEX: 9926) has reported that its bispecific antibody ivonescimab improved overall ...
Seeking Alpha

Merck Keytruda combo fails lung cancer trial, sees another setback in prostate cancer

Merck (NYSE:MRK) is discontinuing a phase 3 trial of a Keytruda combination treatment for prostate cancer after the study failed its main goals, while another late stage trial of the blockbuster drug ...
Nasdaq

FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Stage IB (≥4 centimeters)-IIIA Non-Small Cell Lung Cancer Following Complete Surgical ...

Acceptance based on results from the Phase 3 KEYNOTE-091 trial, the seventh positive pivotal study evaluating a KEYTRUDA-based regimen in earlier stages of cancer The study has dual primary endpoints ...
Nasdaq

European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults With Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA, Merck’s anti-PD-1 ...